X4 Pharmaceuticals (XFOR) Payables (2017 - 2025)

X4 Pharmaceuticals has reported Payables for 9 years, with the latest figure at $5.7 million in Q4 2025.

• For the quarter ending Q4 2025, Payables fell 33.93% year-over-year to $5.7 million; the trailing twelve-month figure through Dec 2025 stood at $5.7 million (down 33.93% YoY), and the FY2025 full-year result was $5.7 million, down 33.93% from the prior year.
• Payables for Q4 2025 stood at $5.7 million, up from $5.1 million in the prior quarter.
• The five-year high for Payables was $11.1 million in Q1 2025, with the low at $2.4 million in Q3 2021.
• Historically, Payables has averaged $6.2 million across 5 years, with a median of $5.8 million in 2023.
• Annual changes were most pronounced in 2021 — Payables jumped 147.68% — and 2025, when it slumped 41.09%.
• X4 Pharmaceuticals' Payables stood at $4.3 million in 2021, then soared by 81.58% to $7.8 million in 2022, then increased by 15.04% to $8.9 million in 2023, then declined by 3.64% to $8.6 million in 2024, then slumped by 33.93% to $5.7 million in 2025.
• The last three Payables figures came in at $5.7 million (Q4 2025), $5.1 million (Q3 2025), and $7.7 million (Q2 2025), per Business Quant data.